GlassScriptPhysician profile
Robert I Kodsi
NPI 1710979158
$618.05
in general payments reported to CMS, 2019-2025
12 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.61 · 2022: $109 · 2023: $72.55 · 2024: $109 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.91 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.13 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.16 | 2023-2024 | Xifaxan |
| Lilly USA, LLC | $48.01 | 2024 | Omvoh, Zepbound |
| Aimmune Therapeutics, INC. | $36.26 | 2025 | Zenpep |
| Boston Scientific Corporation | $35.20 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $27.15 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $25.27 | 2025 | Dupixent |
| Ardelyx, INC. | $18.84 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $17.68 | 2025 | Sutab, Suflave |
| Celltrion USA INC. | $17.66 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kodsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.